Somatuline set for further growth after new FDA nod

Rising sales of Somatuline (lanreotide) are set to grow further after it was approved in a second indication by the US Food and Drug Administration (FDA).

The regulator has approved a supplemental indication for Somatuline Depot (lanreotide) injection 120mg for the treatment of carcinoid syndrome. When used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.

Somatuline is already approved for the improvement of progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).